Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Dec 12, 2024 · CIK: 882361
Sentiment: neutral
Topics: sec-filing, regulation-fd, financials
Related Tickers: APTO
TL;DR
APTO files 8-K, check for Reg FD and financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on December 12, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is based in Toronto, Canada, and operates in the biological products sector.
Why It Matters
This filing provides official updates and disclosures from Aptose Biosciences Inc. to the SEC, which are important for investors to monitor company activities and compliance.
Risk Assessment
Risk Level: low — This is a routine SEC filing and does not contain specific financial or operational news that would inherently increase risk.
Key Numbers
- 001-32001 — SEC File Number (Identifier for the company's filings with the SEC)
- 98-1136802 — IRS Number (Tax identification number for the company)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- December 12, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for Aptose Biosciences Inc., reporting under Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 12, 2024.
What are the former names of Aptose Biosciences Inc. mentioned in the filing?
The filing mentions that Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Where is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?
The SIC code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-12-12 10:30:11
Filing Documents
- f8k_121224.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-006898.txt ( ) — 224KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_121224_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 12, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: December 12, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer